Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
With Growing Rate of Childhood Myopia, MIRA-4 Trial Supports a Potential Broader RM Label for Nyxol in Pediatric Subjects 3 to 11 Years Ocuphire Delivering on Execution Early in 2022, Momentum Builds...
-
Completed enrollment ahead of schedule in second Phase 3 FDA registration trial for Nyxol in RM (MIRA-3) with top-line results expected soon around the end of 1Q22 VEGA-1 Phase 2 data showing the...
-
New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients...
-
Update on Late-Stage Clinical Trials in the APX3330 and Nyxol Programs as well as Commercial Insights for Nyxol for RM and Presbyopia by Six Leading KOLs Webinar to Take Place on Monday, January 31st...
-
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial Initiated Enrollment of Nyxol MIRA-4 Pediatric Study in RM per Agreed Initial Pediatric Study Plan with FDA Nyxol MIRA-3 Phase 3 Results,...
-
FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
RM Indication Allows for Rapid Recruitment with Top-line Results Expected in Early 2022 Nyxol has the Potential Opportunity to Address Estimated $500M+ Reversal of Dilation Market with No Approved...
-
On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol® Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and Presbyopia in 1H22 Three Clinical Trial Data Readouts Expected in Early...
-
FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 Ocuphire Uniquely Positioned in Developing Late-Stage Innovative...